FDA Announces Regulatory Review Period for Attruby
February 13, 2026
February 13, 2026
WASHINGTON, Feb. 13 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration published a notice establishing the regulatory review period for the drug Attruby. This determination follows applications filed by Bridgebio Pharma Inc., Palo Alto, California, with the U.S. Department of Commerce Patent and Trademark Office for the extension of several patents associated with the product.
Attruby, also known as acoramidis, is an oral medication approved for . . .
Attruby, also known as acoramidis, is an oral medication approved for . . .